Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812993 | 0.91 | CA1 (0.38) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL3812504 | 0.86 | PYGB (0.40) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL2510604 | 0.83 | ADORA1 (0.44) | CA1CA2CA9AKR1B1 | |
| SCHEMBL8329378 | 0.83 | ADORA1 (0.44) | CA1CA2CA9AKR1B1 | |
| SCHEMBL3816161 | 0.83 | CA1 (0.37) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL3810831 | 0.81 | CA1 (0.50) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL6934741 | 0.81 | CA1 (0.50) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL7253811 | 0.81 | CA1 (0.50) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL9616492 | 0.81 | CA1 (0.50) | CA1CA2CA9PYGBAKR1B1 | |
| SCHEMBL18642492 | 0.81 | CA1 (0.50) | CA1CA2CA9PYGBAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863497-A4 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1863497-A2 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006105167-A2 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |